BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rabaan AA, Al-Ahmed SH, Bazzi AM, Alfouzan WA, Alsuliman SA, Aldrazi FA, Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J Infect Public Health 2020;13:773-83. [PMID: 31870632 DOI: 10.1016/j.jiph.2019.11.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Bernier C, Goetz C, Jubinville E, Jean J. The New Face of Berries: A Review of Their Antiviral Proprieties. Foods 2021;11:102. [PMID: 35010229 DOI: 10.3390/foods11010102] [Reference Citation Analysis]
2 Khayat MT, Omar AM, Elfaky MA, Muhammad YA, Felemban EA, El-say KM, El-araby ME, Xie J. Reexamining Povarov Reaction’s Scope and Limitation in the Generation of HCV-NS4A Peptidomimetics. Heteroatom Chemistry 2022;2022:1-12. [DOI: 10.1155/2022/8181543] [Reference Citation Analysis]
3 Zhu S, Liu B, Xu Y, Zhang L, Xia Z, Liu J, Zhou X, Fu Y, Allain J, Li C, Li T. Two New Purification Methods of Hepatitis C Virus Particles from Serum-Free Culture System. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.115727] [Reference Citation Analysis]
4 Hagymási K. The Nobel Prize in Physiology or Medicine-2020. Struct Chem 2021;:1-5. [PMID: 33584076 DOI: 10.1007/s11224-021-01731-z] [Reference Citation Analysis]
5 Ejeh S, Uzairu A, Shallangwa GA, Abechi SE. Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors. Bull Natl Res Cent 2021;45. [DOI: 10.1186/s42269-020-00467-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Badami E, Busà R, Douradinha B, Russelli G, Miceli V, Gallo A, Zito G, Conaldi PG, Iannolo G. Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches. World J Gastroenterol 2022; 28(22): 2417-2428 [DOI: 10.3748/wjg.v28.i22.2417] [Reference Citation Analysis]
7 Arba M, Wahyudi ST, Zubair MS, Brunt D, Singh M, Wu C. Binding of GS-461203 and Its Halogen Derivatives to HCV Genotype 2a RNA Polymerase Drug Resistance Mutants. Sci Pharm 2022;90:26. [DOI: 10.3390/scipharm90020026] [Reference Citation Analysis]
8 Yadav SR, Goldman DA, Murray KF. Hepatitis C: Current State of Treatment in Children. Pediatr Clin North Am 2021;68:1321-31. [PMID: 34736592 DOI: 10.1016/j.pcl.2021.07.008] [Reference Citation Analysis]
9 Matsumoto T, Tsuchiya T, Hirano T, Laurent T, Matsunaga K, Takata J. Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database. Clinicoecon Outcomes Res 2021;13:145-53. [PMID: 33658813 DOI: 10.2147/CEOR.S293698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sinopoli A, Isonne C, Santoro MM, Baccolini V. The effects of orally administered lactoferrin in the prevention and management of viral infections: A systematic review. Rev Med Virol 2021;:e2261. [PMID: 34133812 DOI: 10.1002/rmv.2261] [Reference Citation Analysis]
11 Mirzaie S, Abdi F, GhavamiNejad A, Lu B, Wu XY. Covalent Antiviral Agents. Adv Exp Med Biol 2021;1322:285-312. [PMID: 34258745 DOI: 10.1007/978-981-16-0267-2_11] [Reference Citation Analysis]